Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Glyxambi

×

Overview

What is Glyxambi?

GLYXAMBI tablets contain two oral antihyperglycemic drugs used in the management of type 2 diabetes: empagliflozin and linagliptin.

Empagliflozin

The chemical name of empagliflozin is D-Glucitol,1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, (1S).

The molecular formula is CHClO and the molecular weight is 450.91. The structural formula is:

Empagliflozin is a white to yellowish, non-hygroscopic powder. It is very slightly soluble in water, sparingly soluble in methanol, slightly soluble in ethanol and acetonitrile; soluble in 50% acetonitrile/water; and practically insoluble in toluene.

Linagliptin

The chemical name of linagliptin is 1H-Purine-2,6-dione, 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-

The molecular formula is CHNO and the molecular weight is 472.54. The structural formula is:

Linagliptin is a white to yellowish, not or only slightly hygroscopic solid substance. It is very slightly soluble in water. Linagliptin is soluble in methanol, sparingly soluble in ethanol, very slightly soluble in isopropanol, and very slightly soluble in acetone.

GLYXAMBI



What does Glyxambi look like?



What are the available doses of Glyxambi?

Tablets:

10 mg empagliflozin/5 mg linagliptin

25 mg empagliflozin/5 mg linagliptin ()

What should I talk to my health care provider before I take Glyxambi?

How should I use Glyxambi?

GLYXAMBI is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate.

Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease . However, the effectiveness of GLYXAMBI on reducing the risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease has not been established.

Limitations of Use

[see Warnings and Precautions ()]

GLYXAMBI has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using GLYXAMBI

The recommended dose of GLYXAMBI is 10 mg empagliflozin/5 mg linagliptin once daily in the morning, taken with or without food. In patients tolerating GLYXAMBI, the dose may be increased to 25 mg empagliflozin/5 mg linagliptin once daily.

In patients with volume depletion, correcting this condition prior to initiation of GLYXAMBI is recommended

No studies have been performed specifically examining the safety and efficacy of GLYXAMBI in patients previously treated with other oral antihyperglycemic agents and switched to GLYXAMBI. Any change in therapy of type 2 diabetes should be undertaken with care and appropriate monitoring as changes in glycemic control can occur.


What interacts with Glyxambi?

Sorry No Records found


What are the warnings of Glyxambi?

Sorry No Records found


What are the precautions of Glyxambi?

Sorry No Records found


What are the side effects of Glyxambi?

Sorry No records found


What should I look out for while using Glyxambi?

GLYXAMBI is contraindicated in patients with:


What might happen if I take too much Glyxambi?

In the event of an overdose with GLYXAMBI, contact the Poison Control Center. Employ the usual supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive treatment) as dictated by the patient’s clinical status. Removal of empagliflozin by hemodialysis has not been studied, and removal of linagliptin by hemodialysis or peritoneal dialysis is unlikely.


How should I store and handle Glyxambi?

Store LONHALA Inhalation Solution in the protective foil pouch at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Always use the MAGNAIR Replacement Handset parts that come with each LONHALA MAGNAIR refill prescription. Keep out of the reach of children. Store LONHALA Inhalation Solution in the protective foil pouch at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Always use the MAGNAIR Replacement Handset parts that come with each LONHALA MAGNAIR refill prescription. Keep out of the reach of children. Store LONHALA Inhalation Solution in the protective foil pouch at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Always use the MAGNAIR Replacement Handset parts that come with each LONHALA MAGNAIR refill prescription. Keep out of the reach of children. GLYXAMBI (empagliflozin and linagliptin) tablets are available in 10 mg/5 mg and 25 mg/5 mg strengths as follows:10 mg/5 mg tablets:Bottles of 30 (NDC 0597-0182-30)Bottles of 90 (NDC 0597-0182-90)Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0182-39), institutional pack.25 mg/5 mg tablets:Bottles of 30 (NDC 0597-0164-30)Bottles of 90 (NDC 0597-0164-90)Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0164-39), institutional pack.If repackaging is required, dispense in a tight container as defined in USP.StorageStore at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F)GLYXAMBI (empagliflozin and linagliptin) tablets are available in 10 mg/5 mg and 25 mg/5 mg strengths as follows:10 mg/5 mg tablets:Bottles of 30 (NDC 0597-0182-30)Bottles of 90 (NDC 0597-0182-90)Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0182-39), institutional pack.25 mg/5 mg tablets:Bottles of 30 (NDC 0597-0164-30)Bottles of 90 (NDC 0597-0164-90)Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0164-39), institutional pack.If repackaging is required, dispense in a tight container as defined in USP.StorageStore at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F)GLYXAMBI (empagliflozin and linagliptin) tablets are available in 10 mg/5 mg and 25 mg/5 mg strengths as follows:10 mg/5 mg tablets:Bottles of 30 (NDC 0597-0182-30)Bottles of 90 (NDC 0597-0182-90)Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0182-39), institutional pack.25 mg/5 mg tablets:Bottles of 30 (NDC 0597-0164-30)Bottles of 90 (NDC 0597-0164-90)Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0164-39), institutional pack.If repackaging is required, dispense in a tight container as defined in USP.StorageStore at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F)GLYXAMBI (empagliflozin and linagliptin) tablets are available in 10 mg/5 mg and 25 mg/5 mg strengths as follows:10 mg/5 mg tablets:Bottles of 30 (NDC 0597-0182-30)Bottles of 90 (NDC 0597-0182-90)Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0182-39), institutional pack.25 mg/5 mg tablets:Bottles of 30 (NDC 0597-0164-30)Bottles of 90 (NDC 0597-0164-90)Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0164-39), institutional pack.If repackaging is required, dispense in a tight container as defined in USP.StorageStore at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F)GLYXAMBI (empagliflozin and linagliptin) tablets are available in 10 mg/5 mg and 25 mg/5 mg strengths as follows:10 mg/5 mg tablets:Bottles of 30 (NDC 0597-0182-30)Bottles of 90 (NDC 0597-0182-90)Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0182-39), institutional pack.25 mg/5 mg tablets:Bottles of 30 (NDC 0597-0164-30)Bottles of 90 (NDC 0597-0164-90)Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0164-39), institutional pack.If repackaging is required, dispense in a tight container as defined in USP.StorageStore at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F)GLYXAMBI (empagliflozin and linagliptin) tablets are available in 10 mg/5 mg and 25 mg/5 mg strengths as follows:10 mg/5 mg tablets:Bottles of 30 (NDC 0597-0182-30)Bottles of 90 (NDC 0597-0182-90)Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0182-39), institutional pack.25 mg/5 mg tablets:Bottles of 30 (NDC 0597-0164-30)Bottles of 90 (NDC 0597-0164-90)Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0164-39), institutional pack.If repackaging is required, dispense in a tight container as defined in USP.StorageStore at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F)GLYXAMBI (empagliflozin and linagliptin) tablets are available in 10 mg/5 mg and 25 mg/5 mg strengths as follows:10 mg/5 mg tablets:Bottles of 30 (NDC 0597-0182-30)Bottles of 90 (NDC 0597-0182-90)Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0182-39), institutional pack.25 mg/5 mg tablets:Bottles of 30 (NDC 0597-0164-30)Bottles of 90 (NDC 0597-0164-90)Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0164-39), institutional pack.If repackaging is required, dispense in a tight container as defined in USP.StorageStore at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F)GLYXAMBI (empagliflozin and linagliptin) tablets are available in 10 mg/5 mg and 25 mg/5 mg strengths as follows:10 mg/5 mg tablets:Bottles of 30 (NDC 0597-0182-30)Bottles of 90 (NDC 0597-0182-90)Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0182-39), institutional pack.25 mg/5 mg tablets:Bottles of 30 (NDC 0597-0164-30)Bottles of 90 (NDC 0597-0164-90)Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0164-39), institutional pack.If repackaging is required, dispense in a tight container as defined in USP.StorageStore at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F)


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

GLYXAMBI

Empagliflozin

Linagliptin

Non-Clinical Toxicology
GLYXAMBI is contraindicated in patients with:

If phenytoin or other hepatic enzyme inducers are taken concurrently with disopyramide, lower plasma levels of disopyramide may occur. Monitoring of disopyramide plasma levels is recommended in such concurrent use to avoid ineffective therapy. Other antiarrhythmic drugs (e.g., quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with disopyramide. Excessive widening of the QRS complex and/or prolongation of the Q-T interval may occur in these situations (see ). In healthy subjects, no significant drug-drug interaction was observed when disopyramide was coadministered with either propranolol or diazepam. Concomitant administration of disopyramide and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels. Disopyramide does not increase serum digoxin levels.

Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.

Although potent inhibitors of CYP3A4 (e.g., ketoconazole) have not been studied clinically, studies have shown that erythromycin and oleandomycin inhibit the metabolism of disopyramide. Cases of life-threatening interactions have been reported for disopyramide when given with clarithromycin and erythromycin indicating that co-administration of disopyramide with inhibitors of CYP3A4 could result in potentially fatal interaction.

There have been postmarketing reports of acute pancreatitis, including fatal pancreatitis, in patients taking linagliptin. Take careful notice of potential signs and symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue GLYXAMBI and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using GLYXAMBI.

The following important adverse reactions are described below and elsewhere in the labeling:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).